507 related articles for article (PubMed ID: 15127421)
1. Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions.
Fenwick E; O'Brien BJ; Briggs A
Health Econ; 2004 May; 13(5):405-15. PubMed ID: 15127421
[TBL] [Abstract][Full Text] [Related]
2. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness acceptability curves--caveats quantified.
Jakubczyk M; Kamiński B
Health Econ; 2010 Aug; 19(8):955-63. PubMed ID: 19688780
[TBL] [Abstract][Full Text] [Related]
4. The adoption of cost-effectiveness acceptability curves in cost-utility analyses.
Meckley LM; Greenberg D; Cohen JT; Neumann PJ
Med Decis Making; 2010; 30(3):314-9. PubMed ID: 19773582
[TBL] [Abstract][Full Text] [Related]
5. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI).
Barton GR; Briggs AH; Fenwick EA
Value Health; 2008; 11(5):886-97. PubMed ID: 18489513
[TBL] [Abstract][Full Text] [Related]
6. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.
Fenwick E; Marshall DA; Levy AR; Nichol G
BMC Health Serv Res; 2006 Apr; 6():52. PubMed ID: 16623946
[TBL] [Abstract][Full Text] [Related]
7. The augmented representation of the cost-effectiveness acceptability curve for economic evaluation of health technology.
Araki D; Kamae I
Kobe J Med Sci; 2015 Mar; 61(1):E9-18. PubMed ID: 25868612
[TBL] [Abstract][Full Text] [Related]
8. Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope.
Hoch JS; Rockx MA; Krahn AD
BMC Health Serv Res; 2006 Jun; 6():68. PubMed ID: 16756680
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness acceptability curves and a reluctance to lose.
Severens JL; Brunenberg DE; Fenwick EA; O'Brien B; Joore MA
Pharmacoeconomics; 2005; 23(12):1207-14. PubMed ID: 16336015
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness acceptability curves revisited.
Al MJ
Pharmacoeconomics; 2013 Feb; 31(2):93-100. PubMed ID: 23329426
[TBL] [Abstract][Full Text] [Related]
11. Handling Uncertainty in Cost-Effectiveness Analysis: Budget Impact and Risk Aversion.
Sendi P; Matter-Walstra K; Schwenkglenks M
Healthcare (Basel); 2021 Oct; 9(11):. PubMed ID: 34828466
[TBL] [Abstract][Full Text] [Related]
12. Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison.
Wolff HB; Qendri V; Kunst N; Alarid-Escudero F; Coupé VMH
Med Decis Making; 2022 Oct; 42(7):956-968. PubMed ID: 35587181
[TBL] [Abstract][Full Text] [Related]
13. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods.
O'Brien BJ; Briggs AH
Stat Methods Med Res; 2002 Dec; 11(6):455-68. PubMed ID: 12516984
[TBL] [Abstract][Full Text] [Related]
14. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
Negrín MA; Vázquez-Polo FJ
J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
[TBL] [Abstract][Full Text] [Related]
15. Representing uncertainty: the role of cost-effectiveness acceptability curves.
Fenwick E; Claxton K; Sculpher M
Health Econ; 2001 Dec; 10(8):779-87. PubMed ID: 11747057
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
17. Beyond the cost-effectiveness acceptability curve: The appropriateness of rank probabilities for presenting the results of economic evaluation in multiple technology appraisal.
Epstein D
Health Econ; 2019 Jun; 28(6):801-807. PubMed ID: 31050043
[TBL] [Abstract][Full Text] [Related]
18. "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.
Alarid-Escudero F; Enns EA; Kuntz KM; Michaud TL; Jalal H
Value Health; 2019 May; 22(5):611-618. PubMed ID: 31104743
[TBL] [Abstract][Full Text] [Related]
19. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
Noyes K; Dick AW; Holloway RG;
Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
[TBL] [Abstract][Full Text] [Related]
20. Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses.
Müller D; Pullenayegum E; Gandjour A
Eur J Health Econ; 2015 Mar; 16(2):219-23. PubMed ID: 24840608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
